Neurocrine Biosciences, Inc. unveiled disappointing Phase II data for a first-in-class schizophrenia candidate that the company hoped would address both negative symptoms and cognitive issues related to the disease. The company said on 2 March that it still sees potential for the drug because it hit a pair of secondary endpoints.
Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
More from Clinical Trials
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.